Compare Expensify Inc (EXFY) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Tempus AI — how do they compare? Expensify Inc trades at $2.3 (market cap $206.99M), while Tempus AI trades at $70.41 (market cap $12.77B). The key difference: Tempus AI is far larger — about 61.7× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Tempus AI for 22 Days on average.
| EXFY | TEM | |
|---|---|---|
Market Cap | $206.99M | $12.77B |
Volume | 256,089 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.72 | $99.28 |
52-Week Low | $0.75 | $41.55 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | $146.61M | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.27, up 1.79% on the day, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 earnings of $0.04 per share, beating estimates, and raised free cash flow guidance. Revenue trends show stabilization around $140M annually, though net income remains negative. Recent news highlights AI-native ERP integrations and European card expansion, signaling growth initiatives.
The outlook is mixed: analyst consensus is bullish with a $13.75 price target, but high P/E of 258.82 and persistent losses pose valuation risks. Investment opportunity lies in execution of AI-driven products and cash flow improvement, while key risks include competitive pressure and failure to achieve sustained profitability.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
